Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our commitment to drive greater affordability for both clients and members, we finalized decisions that will affect our formularies on October 1, 2023. Focused on lowest net cost, our decisions strive to provide the most benefit to both clients and members.
HUMIRA and biosimilars
Beginning in February 2023 and culminating in July 2023, ten biosimilar products to Humira have been released. These products are designed to have the same clinical effect as those of a reference drug that has previously been licensed. Current biosimilars now available to Humira are as follows:
- Adalimumab-adaz (Sandoz)
- Adalimumab-fkjp (Mylan)
- Amjevita™ (Amgen)
- Cyltezo® (Boehringer Ingelheim)
- Hadlima™(Organon)
- Hulio® (Mylan)
- Hyrimoz® (Sandoz)
- Idacio® (Fresenius Kabi)
- Yuflyma® (Celltrion)
- Yusimry® (Coherus)
Formulary Updates
Due to these releases, additional rebates are now being offered from Abbvie, the manufacturer of Humira. In addition, significant cost savings compared to Humira are now available for the biosimilars listed above. With the complexity of upfront product costs, availability of rebates, manufacturer rebate bundling, and patient copay assistance, the Navitus formularies will be updated on October 1, 2023 with the following:
Added:
- Adalimumab-adaz
- Adalimumab-fkjp
- Hadlima™
Remaining: Humira
Removed: Amjevita™
Our teams will continue to monitor the evolving landscape of biosimiliar products and drug pipeline activity to keep you informed.
|
|
WRITTEN BY BRENT EBERLE As Senior Vice President, Chief Pharmacy Officer, Brent oversees Navitus’ health strategies division, which is responsible for clinical and population health initiatives, drug utilization review programs, formulary and rebate management, and specialty pharmacy operations.
|
